Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 47Lung Neoplasms 23Carcinoma, Hepatocellular 23Small Cell Lung Carcinoma 16Cholangiocarcinoma 10Breast Neoplasms 10Urinary Bladder Neoplasms 9Biliary Tract Neoplasms 9Neoplasms 8Neoplasm Metastasis 8Liver Neoplasms 8Pancreatic Neoplasms 6Carcinoma 6Endometrial Neoplasms 5Triple Negative Breast Neoplasms 4Non-Muscle Invasive Bladder Neoplasms 4Gallbladder Neoplasms 4Carcinoma, Transitional Cell 4Ovarian Neoplasms 3Neoplasms by Site 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Bile Duct Neoplasms 3Adenocarcinoma 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Respiratory Tract Neoplasms 2Pathologic Complete Response 2Oropharyngeal Neoplasms 2Neoplasms by Histologic Type 2

Interventions

pembrolizumab 1osimertinib 1durvalumab 1AZD 6244 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Non Small Cell Lung Cancer × durvalumab × 90 days × Clear all
NCT02143466 2026-04-24

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

AstraZeneca

Phase 1 Active not recruiting
344 enrolled
Thoracic

Advanced Non Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡